Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer
Open accessAbstract
Background and Purpose. The mevalonate pathway is one of the major metabolic pathways that use acetyl-CoA to produce sterols and isoprenoids. These compounds can be effective in the growth and development of tumors. One of the enzymes involved in the mevalonate pathway is FDFT1. Different variants of this gene are involved in the risk of suffering various diseases. The present study examined the relationship between FDFT1 rs2645429 polymorphism and the risk of nonsmall cell lung cancer (NSCLC) in a population from southern Iran.Method. The genotypes of rs2645429 polymorphism of FDFT1 gene were examined in 95 samples: 34 patients with NSCLC and 61 healthy individuals by RFLP method.Results. The results of this study indicated that C allele of this polymorphism was effectively associated with the risk of NSCLC in the Iranian population (pvalue = 0.023; OR = 2.71; 95% CI = 1.12–6.59) and CC genotype has significant relation with susceptibility to NSCLC (pvalue = 0.029; OR = 3.02; 95% CI = 1.09–8.39). This polymorphism is located in the promoter region FDFT1 gene, and CC genotype may increase the activity of this promoter. This study also found a significant relationship between C allele and metastatic status. C allele was more common in NSCLC patients. (p=0.04).Conclusion. C allele of FDFT1 rs2645429 polymorphism gene can be a risk factor for NSCLC, whereas T allele probably has a low protective role.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FDFT1 has seldom been studied in cancer research; limited studies addressed FDFT1 in prostate cancer, ovarian cancer, and lung cancer, but there is no information on the function of FDFT1 in CRC.
“Limited studies addressed FDFT1 in prostate cancer35, ovarian cancer46, and lung cancer47, but there is no information on the function of FDFT1 in CRC.”
From RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression (2020) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 47 · Cited by 9
Research works printed but not linked: 1
- [3]Behera D. Epidemiology of lung cancer-global and Indian perspective Journal Indian Academy of Clinical Medicine 2012 13 131 137
- Authors
- Dehghani, M., Samani, Z., Abidi, H., Manzouri, L., Mahmoudi, R., Hosseini Teshnizi, S., & Nikseresht, M.
- Affiliations
- Shiraz University of Medical Sciences (IR)
- Yasuj University of Medical Sciences (IR)
- Biostatistican, Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
- Corresponding author
- Nikseresht, Mohsen
- ORCID
- Venue
- International Journal of Genomics
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-7
- ISSN
- 2314-436X (ISSN-L)
- 2314-4378
- PMC
- PMC5885393
- OpenAlex
- W2791315682
- Cited by
- 9
- References
- 47
- Citations by year
- 2026: 1 · 2025: 2 · 2022: 3 · 2020: 3
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Genomics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Yasuj University of Medical Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- FDFT1, promoter polymorphism, non-small cell lung cancer, genetic susceptibility, mevalonate pathway, terpenoids, metastasis, Iranian population
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
